Can Hu
Impact in
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Oncology top 10%
- Drug Transport and Resistance Mechanisms
Papers in
-
- Gastric Cancer Management and Outcomes 31
- Metastasis and carcinoma case studies 14
- Co-authors
- Xiangdong Cheng (25 shared papers)Yuan Li (20 shared papers)Jiang‐Jiang Qin (10 shared papers)Zhiyuan Xu (28 shared papers)Jinyun Dong (4 shared papers)Yanqiang Zhang (27 shared papers)Hang Lv (7 shared papers)Xiangdong Cheng (18 shared papers)
- Journals
- Journal of Oncology (3 papers)Annals of Translational Medicine (3 papers)Cancer Biology and Medicine (3 papers)Frontiers in Oncology (3 papers)Nature Communications (2 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Can Hu
85 papers receiving 1.0k citations
Hit Papers
Peers
Comparison fields: 5 of 129
- Cancer Research 197
- Oncology 308
- Gastroenterology 55
- Pulmonary and Respiratory Medicine 279
- Aging 14
Countries citing papers authored by Can Hu
This map shows the geographic impact of Can Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Can Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Can Hu more than expected).
Fields of papers citing papers by Can Hu
This network shows the impact of papers produced by Can Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Can Hu. The network helps show where Can Hu may publish in the future.
Co-authors
The 25 scholars most cited alongside Can Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 95 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors Hit paper breakdown → | 2024 | 87 |
| 2 | Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review Hit paper breakdown → | 2023 | 85 |
| 3 | 2021 | 44 | |
| 4 | 2020 | 44 | |
| 5 | 2023 | 40 | |
| 6 | 2024 | 39 | |
| 7 | 2023 | 36 | |
| 8 | 2018 | 32 | |
| 9 | 2019 | 31 | |
| 10 | eIF5A2 regulates the resistance of gastric cancer cells to cisplatin via induction of EMT. | 2018 | 29 |
| 11 | 2023 | 26 | |
| 12 | 2023 | 25 | |
| 13 | 2023 | 25 | |
| 14 | 2023 | 24 | |
| 15 | 2020 | 24 | |
| 16 | 2016 | 24 | |
| 17 | 2015 | 18 | |
| 18 | 2021 | 16 | |
| 19 | 2024 | 16 | |
| 20 | 2023 | 15 |
About Can Hu
Can Hu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Surgery and Cancer Research, having authored 95 papers that have together received 1.1k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (31 papers), Metastasis and carcinoma case studies (14 papers), Gastrointestinal Tumor Research and Treatment (12 papers), Esophageal Cancer Research and Treatment (9 papers), Cancer Mechanisms and Therapy (8 papers), Radiomics and Machine Learning in Medical Imaging (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer-related molecular mechanisms research (6 papers). The work is most often cited by research in Cancer Research (197 citations), Oncology (308 citations), Gastroenterology (55 citations), Pulmonary and Respiratory Medicine (279 citations) and Aging (14 citations). Can Hu has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Xiangdong Cheng, Yuan Li, Jiang‐Jiang Qin, Zhiyuan Xu, Jinyun Dong, Yanqiang Zhang, Hang Lv, Xiangdong Cheng, Zhiyuan Xu and Ji‐Xiang Du. Their work appears in journals such as Journal of Oncology, Annals of Translational Medicine, Cancer Biology and Medicine, Frontiers in Oncology and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.